Private Banking|Professional Solutions|Investment Management|Investment Banking|About us
Van Lanschot Kempen Logo
  • Solutions
  • Sectors
  • Careers
Dec 2022
molecular partners
Sole Block Placing Agent
1.3 million shares
Block Trade in Molecular Partner Shares

Molecular Partners

Sole Block Placing Agent

Van Lanschot Kempen is pleased to announce that it acted as a Sole Block Placing Agent in the placement of 1.3m Molecular Partners shares

Transaction highlights

  • Van Lanschot Kempen crossed 1.3 million Molecular Partners shares, representing a c. 4.0% of the outstanding share capital
  • The transaction builds on the long-standing relationship between Molecular Partners and Van Lanschot Kempen including its involvement in a block trade of c. 4% of the company’s shares in January 2022, the Nasdaq IPO in 2021, the Accelerated Bookbuild Offering in 2020, and the block trade of c. 5% of the company’s shares in 2019
  • This smoothly executed block trade demonstrates another avenue where Van Lanschot Kempen provides added value to the European life sciences universe and can assist investors by leveraging its strong international investor network to find the right counterparties

Company description

Molecular Partners is a clinical-stage biotech company developing DARPin® therapeutics, a new class of custom-built protein drugs designed to address challenges current modalities cannot. The Company has formed partnerships with leading pharmaceutical companies to advance DARPin® therapeutics in the areas of ophthalmology, oncology and infectious disease, and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.

Van Lanschot Kempen Life Sciences & Healthcare credentials

  • Sole Financial Adviser to Gensight Biologics securing a €35 million credit facility from the European Investment Bank
  • Joint Global Coordinator and Joint Bookrunner in Xbrane’s SEK 170 million Capital Increase
  • Co-Lead Manager in Zealand Pharma’s DKK 786 million Capital Increase
  • Sole Financial Adviser in Mendus’ up to SEK 250 million of financing commitments
  • Sole Financial Adviser in the sale of Sanquin Reagents by Sanquin Health Solutions to Gilde Healthcare
  • Joint Global Coordinator in BioInvent’s SEK 299 million directed share issue
  • Sole Global Coordinator Abliva’s SEK 200 million financing consisting of a SEK 150m PIPE and a SEK 50m Fully Guaranteed Rights Issue
  • Joint Global Coordinator & Joint Bookrunner in SynAct Pharma’s SEK 150 million Fully Guaranteed Rights Issue
  • Co-Manager in the USD 700 million Capital Increase by argenx
  • Sole Block Placing Agent in the placement of 1.4m Molecular Partners shares
  • Joint Bookrunner in the USD 127 million Nasdaq IPO of Forbion European Acquisition Corp
  • Co-Lead Manager in the USD 115 million Nasdaq IPO by IO Biotech

Curious to know more?

Jan de Kerpel Van Lanschot Kempen

Jan de Kerpel

Managing Director                                              Life Sciences and Healthcare

Fully focused on your future

Private Banking
  • Offices
  • Entrepreneurs
  • Healthcare
  • Executives
  • Business professionals
  • Wealth management
  • Conditions
  • Private Banking - Belgium
  • Private Banking - Switzerland

Professional Solutions
Investment Management
Investment Banking

© Van Lanschot Kempen NV 2023About usSecurity and fraud awarenessPrivacy & cookiesDisclaimer